Put the Platform Through an IVD Change Before You Buy It

A compliance-platform demonstration can look convincing when every task stays inside one department. A document moves through approval. A CAPA advances to effectiveness review. A training assignment reaches completion.

Those workflows matter. They still leave an IVD buyer with the harder question: what happens when one product decision crosses the boundaries among regulatory, quality, performance evaluation, supplier management, registration, manufacturing, and postmarket surveillance?

That is where feature lists lose their usefulness.

An IVD compliance platform should be evaluated with a scenario that is difficult enough to expose the operating model underneath the interface. The goal is not to see how many modules the vendor can display. It is to determine whether the platform can preserve one controlled product story while the facts, evidence, and market decisions change.

Feature lists hide the harder buying question

Most buyers begin with familiar capabilities: document control, CAPA, training, audits, supplier management, complaints, and change control. A modern eQMS should handle those quality processes well.

IVD compliance extends beyond them. Intended purpose shapes the evidence strategy. Performance evidence supports claims. Supplier and manufacturing changes can affect assay behavior. Registration and labeling decisions vary by market. Postmarket signals can force the team to reopen risk, performance, or change decisions that appeared settled.

A platform may contain every expected quality module and still require employees to reconstruct these relationships in spreadsheets, email threads, regulatory trackers, shared drives, and specialist systems.

The recent IntelaSolve article on whether an eQMS is enough for medical-device compliance explains that scope problem. For IVD buyers, the next step is more concrete: take one realistic product scenario and ask the platform to carry it through the entire lifecycle.

Use one scenario that crosses the IVD lifecycle

Consider a hypothetical established assay that the manufacturer plans to introduce into a new near-patient setting. The intended user and use environment will change, and the team is assessing whether existing performance evidence supports the proposed intended purpose.

During that work, a supplier announces a manufacturing-process change for a critical reagent. At roughly the same time, postmarket records show a small group of invalid results associated with several recent lots.

This is deliberately demanding. It gives the buyer something more useful than a clean demonstration case.

Ask the vendor to show how the platform would support the decisions created by this scenario. No generic presentation. No separate demonstrations that reset the product context between modules. Use the same assay, intended purpose, evidence, supplier notice, affected lots, markets, and postmarket records from beginning to end.

Start with the exact intended purpose

The first screen should not be a CAPA form. It should be the controlled product definition that gives every later decision its meaning.

For an IVD, that definition may need to identify the analyte or marker, specimen type, test function, target population, intended user, use setting, instrument or configuration, and whether the result is qualitative or quantitative. Market-specific wording and approved claims must remain distinguishable.

Now introduce the proposed near-patient use.

Can the platform show which elements of the intended purpose would change? Can it distinguish a proposed claim from an approved one? Can the buyer see which risk records, performance documents, labels, registrations, procedures, and postmarket plans depend on the current intended purpose?

A platform does not make the regulatory decision. Qualified teams do. The capability under evaluation is whether those teams can see the affected relationships before approving the change.

If the product definition lives in one system while performance evidence, labels, and registrations each carry their own manually maintained version, the demonstration has already exposed a material operating risk.

Follow the performance evidence into the decision

The next question is whether the proposed use is supported by evidence.

For an EU-focused assessment, the performance evaluation may bring together scientific validity, analytical performance, and clinical performance. Other markets may organize or describe the evidence differently. The platform should preserve those market distinctions while keeping them attached to the same product and intended-purpose decision.

Ask the vendor to show the evidence supporting each relevant claim. Then ask what happens when the intended user or setting changes.

Can the team identify which protocols, reports, data sets, literature assessments, risk controls, and conclusions remain applicable? Can it record a gap without losing the relationship to the claim that created it? If new work is required, can the organization connect the plan, approval, execution, result, deviation, and final conclusion?

This is different from the evidence-planning question addressed in the August 19 EU Joint Scientific Consultation article. That article concerns when to seek advice while study decisions can still change. The buyer test here begins after a product strategy exists and asks whether the platform can carry that strategy through execution and later change.

A polished repository can store the final report. A connected compliance platform should let the reviewer follow the decision that the report supports.

Make the supplier change reach every affected record

Now apply the critical-reagent supplier notice.

Supplier management may capture the notice and qualification record. Change control may open an assessment. Those are useful quality functions, but the demonstration should not stop there.

Ask which assays, configurations, specifications, performance claims, risk controls, validation records, manufacturing instructions, stability assumptions, and distributed lots depend on the reagent. The vendor should be able to show how the team identifies those relationships and assigns the necessary reviews.

The impact assessment may conclude that focused verification is sufficient. It may identify broader analytical or clinical work. It may require additional supplier information before a decision can be made. The correct outcome depends on the facts.

What matters for the platform evaluation is whether the conclusion remains connected to the source notice, affected product records, evidence plan, results, approvals, implementation boundary, and any follow-up commitment.

Also test the transition. Which incoming reagent lot is the first affected lot? Which finished-product lots use it? Were old and new materials segregated? Can a complaint investigator later determine which supplier state applied to a particular finished product?

If that answer depends on someone reconciling procurement data, a change record, and manufacturing history outside the compliance environment, the platform has not resolved the critical handoff.

Test the market and registration consequences

A change can be technically acceptable and still require a market-specific regulatory assessment.

Return to the proposed intended-purpose expansion and supplier change. Ask the vendor to show how the platform distinguishes the impact by market. One jurisdiction may require a submission or registration update. Another may require a different labeling action, evidence package, or implementation sequence. A third may not permit the new claim until a separate decision is complete.

The system should preserve the current approved state while proposed changes are under review. It should also show which product version, label, identifier, registration, and evidence package apply in each market.

This is where a global product record becomes more than a master-data exercise. Regulatory status controls what the organization may manufacture, label, distribute, and communicate.

The IntelaSolve global markets view provides relevant context for evaluating market-specific regulatory work. During a platform demonstration, ask to see how one global product change produces distinct market decisions without breaking the connection to the shared technical evidence.

Bring the postmarket signal back into the product record

The invalid-result reports should not sit at the end of the scenario as an isolated complaint exercise.

Ask the platform to connect each report to the applicable product, configuration, software version where relevant, reagent lot, finished-product lot, market, label version, and intended use. Then ask how the team evaluates the cases together.

Do they suggest a handling issue in the proposed use setting? A reagent or process concern? A labeling problem? A performance trend? An unrelated group of cases that does not support escalation?

The platform cannot answer those scientific and regulatory questions on its own. It should give qualified reviewers the evidence needed to answer them and preserve how they reached the conclusion.

If the postmarket review changes the risk assessment, performance evaluation, supplier investigation, CAPA, or market decision, those consequences should remain visible. The team should not have to copy the same conclusion into several systems and hope the records stay aligned.

That closed loop is especially important for IVDs because a result problem can involve product design, specimen handling, reagent performance, software, user behavior, labeling, or the use environment. A complaint category alone rarely tells the full story.

The related article on IVDR clinical evidence as a living system explains why performance evidence cannot be treated as a one-time submission asset. The platform test should show whether postmarket learning can actually reach that evidence system.

Ask the demonstration to prove the evidence chain

A serious buying evaluation should produce visible answers to a short set of questions.

What the buyer should be able to see

1. Which controlled product definition and intended purpose governed the original decision?
2. Which performance evidence supported each affected claim?
3. What triggered the change, and which records were identified as affected?
4. How did supplier, quality, regulatory, clinical, manufacturing, and postmarket owners contribute to one decision?
5. Which market-specific actions had to be completed before implementation?
6. Which lots, labels, registrations, and product versions reflect the approved state?
7. What evidence remained open after implementation, and who owned it?
8. Could a later reviewer reconstruct the full decision without asking employees where the missing records were stored?

Do not let the demonstration substitute navigation for traceability. Moving quickly among several screens proves that the interface is fast. It does not prove that the records share controlled relationships.

Ask the vendor to change one fact halfway through the scenario. Change the proposed use setting. Add a supplier deviation. Identify another affected market. Introduce a new postmarket report.

Then watch what happens.

Does the change produce a visible impact assessment, or does the presenter manually search for everything that might be affected? Does the approved state remain distinguishable from the proposed state? Can the platform preserve the history of the decision after the conclusion changes?

Those moments reveal more than a prepared workflow.

Choose the operating model, then evaluate the platform

IntelaSolve includes modern eQMS capabilities such as document control, CAPA, training, supplier management, audits, and change control. Its verified positioning extends beyond quality into one continuously monitored compliance infrastructure spanning R&D, design and risk, clinical operations, regulatory strategy and submissions, manufacturing and operations, and postmarket surveillance.

That broader scope is relevant to IVD teams because the assay's compliance story does not belong to one department. Intended purpose, performance, change, registration, supply, release, and postmarket evidence are different views of the same regulated product.

The IntelaSolve eQMS overview and the comparison of QMS, eQMS, and connected compliance provide the verified category foundation. They do not replace a buyer's diligence.

Bring the diligence into the demonstration.

Choose one IVD scenario your team finds difficult today. Use the real decision structure, without sharing confidential information, and ask every vendor to show how the platform would preserve it. The right evaluation question is not, "Do you have supplier management, change control, and complaints?"

It is, "Can you show us what happens to this assay when the facts change?"